Tevogen Inc. (TVGNW) stock
TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
$0.09+0.01 (+18.24%)
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
Tevogen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Tevogen's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.57M. For fiscal 2025 it was -$12.33M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.33M | – |
| FY2024 | Dec 31, 2024 | -$12.00M | – |
| FY2023 | Dec 31, 2023 | -$8.17M | – |
| FY2022 | Dec 31, 2022 | -$215.40K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.19M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.86K | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.60K | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.90K | – |
| Q1 FY2022 | Mar 31, 2022 | -$113.04K | – |